2025 Q3 -tulosraportti

45 päivää sitten36 min

Tarjoustasot

Spotlight Stock Market DK

Määrä

Osto

2 515

Myynti

Määrä

5 065

Viimeisimmät kaupat

Aika	Määrä	Ostaja	Myyjä
17.59.37	450	NON	NON
17.59.37	1 675	NON	NON
17.59.37	340	NON	NON
17.59.37	50	AVA	NON
17.44.26	100	NON	NON

Ylin

12,85

VWAP

12,47

Alin

12

VaihtoMäärä

1,6 127 302

VWAP

12,47

Ylin

12,85

Alin

12

VaihtoMäärä

1,6 127 302

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: Quartr, FactSet

Seuraava tapahtuma
2025 Q4 -tulosraportti	26.2.

Menneet tapahtumat
2025 Q3 -tulosraportti	1.12.2025
2025 Q2 -tulosraportti	28.8.2025
2025 Q1 -tulosraportti	25.4.2025
2024 Q4 -tulosraportti	27.2.2025
2024 Q3 -tulosraportti	21.11.2024

Asiakkaat katsoivat myös

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

bugge123
11 t sitten
·
bugge123
11 t sitten
·
Should one buy more?
Scubacore
9 t sitten
Scubacore
9 t sitten
Added another 30% after the good news.
mads83
15 t sitten
·
mads83
15 t sitten
·
I'm playing around a bit with Gemini regarding an upcoming, potential partnership agreement concerning uTREAT / brain cancer. I've asked the bot to compare it with the current partnership agreement with Curium (prostate cancer). When do you here think we'll see a partnership agreement in place? Within 1-2 months? Or will Curasight delay the partnership agreement until ~ May/June, when Phase 1 concludes (or even longer, I wonder)? The analysis is here...it looks quite reasonable...: "Based on the existing agreement with Curium and the latest clinical data for uTREAT®, a qualified comparison can be made of what a future partnership agreement could potentially entail. Here is a direct comparison between the current Curium agreement and the potential that uTREAT® (therapy) possesses: 1. Comparison of agreement values: Curium agreement (uTRACE®) Product: uTRACE® (Diagnostics) Application: Prostate cancer (specific indication) Total value: Up to 70 million USD (~480 million DKK) Milestones: Development and commercial goals Royalties: "Double-digit" (typically 10-15%) Potential uTREAT® agreement Product: uTREAT® (Therapy) Application: Aggressive tumors (e.g. Glioblastoma) Total value: Significantly higher (estimated 300-600+ million USD) Milestones: Larger "upfront" and clinical milestones Royalties: Often higher for therapy (e.g. 15-20%+) 2. Why uTREAT® is more valuable than uTRACE®: There are three main reasons why an agreement based on the news from January 12, 2026, is expected to significantly exceed the Curium agreement: Therapy vs. Diagnostics: Historically, the market for cancer treatment (therapy) is many times larger than the market for diagnostics (scanning). While diagnostics helps find cancer, it is therapy that costs the most and creates the greatest value for pharmaceutical companies. As mentioned in market analyses, the market for glioblastoma treatment is estimated at over 5 billion EUR, while the diagnostics market is significantly smaller. "First-in-class" validation: The news from January 12 confirms for the first time in humans that uTREAT® actually reaches the brain tumor. This enormously reduces the risk ("de-risking") for a partner. The Curium agreement only covered uTRACE for one specific type of cancer (prostate), while uTREAT® can potentially be used for almost all solid tumors (>85%). Platform potential: A partnership agreement for uTREAT® will likely be structured as a "multi-indication" agreement. This means that the value can escalate quickly if the agent also shows effect in, for example, lung cancer or pancreatic cancer. 3. Estimation of size: If Curasight lands a partnership agreement for uTREAT® after their top-line data in Q2 2026, analysts will often look at similar agreements in the radiopharmaceuticals sector (such as Novartis' acquisitions or partnerships). Upfront payment: For uTRACE (Curium), the first milestones were relatively small (e.g. 500,000 USD). For uTREAT®, an upfront payment will likely be in the millions (USD) immediately to secure the rights. Total framework: A total agreement framework of 300-500 million USD is not unrealistic for a promising therapeutic candidate in the early clinical phases, when the platform is already diagnostically validated. Conclusion: A partnership agreement for uTREAT® will likely make the Curium agreement look like a "little brother". While the Curium agreement validated the technology, it is uTREAT® that will drive the really big economic value. Based on links and market practice, we can expect an agreement that is 5-10 times larger in total potential value than the current agreement with Curium.
Scubacore
12 t sitten
·
Scubacore
12 t sitten
·
It is important that Curasight maintains a good relationship with Curium as Curium is currently their supplier of Lu-177. There are of course other suppliers, but the collaboration with Curium is important in this phase of the projects.
alfredoo
16 t sitten
·
alfredoo
16 t sitten
·
Is anyone else wondering why the stock isn't reacting more to the latest positive news, which otherwise removed significant uncertainty in the case - and that it's even falling today? 🤔
TKHansen
15 t sitten
·
TKHansen
15 t sitten
·
So, 60 new owners came in yesterday, that's pretty good. It should rise and it will do so again soon (I think). There's always one or 2 who need cash and therefore sell off. New house, new car, expensive divorce etc ... life.
frufroe
10 t sitten
·
frufroe
10 t sitten
·
🤣🤣🤣🤣
asromadk
1 päivä sitten
·
asromadk
1 päivä sitten
·
Good revenue. If they can follow up now with something new and perhaps something in the pipeline, then it will suddenly get wild.
AllanL
1 päivä sitten
·
AllanL
1 päivä sitten
·
Can it be true that there are 36,000 shares for sale at price 12.5 at close ??? Oh, I'd really like to own them.....and keep them, just for about half a year....😅
AllanL
1 päivä sitten
AllanL
1 päivä sitten
🤣
bmotrader
1 päivä sitten
·
bmotrader
1 päivä sitten
·
Biostock regarding CURAS: https://www.biostock.se/en/2026/01/curasight-presenterar-preliminara-fas-i-data-for-utreat/
mads83
1 päivä sitten
mads83
1 päivä sitten
https://news.futunn.com/hk/post/67275129/curasight-announces-encouraging-preliminary-data-from-phase-1-trial-evaluating?level=1&data_ticket=1768308455937077 All around the world :P

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

Viimeisin

Kaikki uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q3 -tulosraportti

45 päivää sitten36 min

Uutiset

Viimeisin

Kaikki uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

bugge123
11 t sitten
·
bugge123
11 t sitten
·
Should one buy more?
Scubacore
9 t sitten
Scubacore
9 t sitten
Added another 30% after the good news.
mads83
15 t sitten
·
mads83
15 t sitten
·
I'm playing around a bit with Gemini regarding an upcoming, potential partnership agreement concerning uTREAT / brain cancer. I've asked the bot to compare it with the current partnership agreement with Curium (prostate cancer). When do you here think we'll see a partnership agreement in place? Within 1-2 months? Or will Curasight delay the partnership agreement until ~ May/June, when Phase 1 concludes (or even longer, I wonder)? The analysis is here...it looks quite reasonable...: "Based on the existing agreement with Curium and the latest clinical data for uTREAT®, a qualified comparison can be made of what a future partnership agreement could potentially entail. Here is a direct comparison between the current Curium agreement and the potential that uTREAT® (therapy) possesses: 1. Comparison of agreement values: Curium agreement (uTRACE®) Product: uTRACE® (Diagnostics) Application: Prostate cancer (specific indication) Total value: Up to 70 million USD (~480 million DKK) Milestones: Development and commercial goals Royalties: "Double-digit" (typically 10-15%) Potential uTREAT® agreement Product: uTREAT® (Therapy) Application: Aggressive tumors (e.g. Glioblastoma) Total value: Significantly higher (estimated 300-600+ million USD) Milestones: Larger "upfront" and clinical milestones Royalties: Often higher for therapy (e.g. 15-20%+) 2. Why uTREAT® is more valuable than uTRACE®: There are three main reasons why an agreement based on the news from January 12, 2026, is expected to significantly exceed the Curium agreement: Therapy vs. Diagnostics: Historically, the market for cancer treatment (therapy) is many times larger than the market for diagnostics (scanning). While diagnostics helps find cancer, it is therapy that costs the most and creates the greatest value for pharmaceutical companies. As mentioned in market analyses, the market for glioblastoma treatment is estimated at over 5 billion EUR, while the diagnostics market is significantly smaller. "First-in-class" validation: The news from January 12 confirms for the first time in humans that uTREAT® actually reaches the brain tumor. This enormously reduces the risk ("de-risking") for a partner. The Curium agreement only covered uTRACE for one specific type of cancer (prostate), while uTREAT® can potentially be used for almost all solid tumors (>85%). Platform potential: A partnership agreement for uTREAT® will likely be structured as a "multi-indication" agreement. This means that the value can escalate quickly if the agent also shows effect in, for example, lung cancer or pancreatic cancer. 3. Estimation of size: If Curasight lands a partnership agreement for uTREAT® after their top-line data in Q2 2026, analysts will often look at similar agreements in the radiopharmaceuticals sector (such as Novartis' acquisitions or partnerships). Upfront payment: For uTRACE (Curium), the first milestones were relatively small (e.g. 500,000 USD). For uTREAT®, an upfront payment will likely be in the millions (USD) immediately to secure the rights. Total framework: A total agreement framework of 300-500 million USD is not unrealistic for a promising therapeutic candidate in the early clinical phases, when the platform is already diagnostically validated. Conclusion: A partnership agreement for uTREAT® will likely make the Curium agreement look like a "little brother". While the Curium agreement validated the technology, it is uTREAT® that will drive the really big economic value. Based on links and market practice, we can expect an agreement that is 5-10 times larger in total potential value than the current agreement with Curium.
Scubacore
12 t sitten
·
Scubacore
12 t sitten
·
It is important that Curasight maintains a good relationship with Curium as Curium is currently their supplier of Lu-177. There are of course other suppliers, but the collaboration with Curium is important in this phase of the projects.
alfredoo
16 t sitten
·
alfredoo
16 t sitten
·
Is anyone else wondering why the stock isn't reacting more to the latest positive news, which otherwise removed significant uncertainty in the case - and that it's even falling today? 🤔
TKHansen
15 t sitten
·
TKHansen
15 t sitten
·
So, 60 new owners came in yesterday, that's pretty good. It should rise and it will do so again soon (I think). There's always one or 2 who need cash and therefore sell off. New house, new car, expensive divorce etc ... life.
frufroe
10 t sitten
·
frufroe
10 t sitten
·
🤣🤣🤣🤣
asromadk
1 päivä sitten
·
asromadk
1 päivä sitten
·
Good revenue. If they can follow up now with something new and perhaps something in the pipeline, then it will suddenly get wild.
AllanL
1 päivä sitten
·
AllanL
1 päivä sitten
·
Can it be true that there are 36,000 shares for sale at price 12.5 at close ??? Oh, I'd really like to own them.....and keep them, just for about half a year....😅
AllanL
1 päivä sitten
AllanL
1 päivä sitten
🤣
bmotrader
1 päivä sitten
·
bmotrader
1 päivä sitten
·
Biostock regarding CURAS: https://www.biostock.se/en/2026/01/curasight-presenterar-preliminara-fas-i-data-for-utreat/
mads83
1 päivä sitten
mads83
1 päivä sitten
https://news.futunn.com/hk/post/67275129/curasight-announces-encouraging-preliminary-data-from-phase-1-trial-evaluating?level=1&data_ticket=1768308455937077 All around the world :P

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Spotlight Stock Market DK

Määrä

Osto

2 515

Myynti

Määrä

5 065

Viimeisimmät kaupat

Aika	Määrä	Ostaja	Myyjä
17.59.37	450	NON	NON
17.59.37	1 675	NON	NON
17.59.37	340	NON	NON
17.59.37	50	AVA	NON
17.44.26	100	NON	NON

Ylin

12,85

VWAP

12,47

Alin

12

VaihtoMäärä

1,6 127 302

VWAP

12,47

Ylin

12,85

Alin

12

VaihtoMäärä

1,6 127 302

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Asiakkaat katsoivat myös

Yhtiötapahtumat

Datan lähde: Quartr, FactSet

Seuraava tapahtuma
2025 Q4 -tulosraportti	26.2.

Menneet tapahtumat
2025 Q3 -tulosraportti	1.12.2025
2025 Q2 -tulosraportti	28.8.2025
2025 Q1 -tulosraportti	25.4.2025
2024 Q4 -tulosraportti	27.2.2025
2024 Q3 -tulosraportti	21.11.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q3 -tulosraportti

45 päivää sitten36 min

Uutiset

Viimeisin

Kaikki uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: Quartr, FactSet

Seuraava tapahtuma
2025 Q4 -tulosraportti	26.2.

Menneet tapahtumat
2025 Q3 -tulosraportti	1.12.2025
2025 Q2 -tulosraportti	28.8.2025
2025 Q1 -tulosraportti	25.4.2025
2024 Q4 -tulosraportti	27.2.2025
2024 Q3 -tulosraportti	21.11.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

bugge123
11 t sitten
·
bugge123
11 t sitten
·
Should one buy more?
Scubacore
9 t sitten
Scubacore
9 t sitten
Added another 30% after the good news.
mads83
15 t sitten
·
mads83
15 t sitten
·
I'm playing around a bit with Gemini regarding an upcoming, potential partnership agreement concerning uTREAT / brain cancer. I've asked the bot to compare it with the current partnership agreement with Curium (prostate cancer). When do you here think we'll see a partnership agreement in place? Within 1-2 months? Or will Curasight delay the partnership agreement until ~ May/June, when Phase 1 concludes (or even longer, I wonder)? The analysis is here...it looks quite reasonable...: "Based on the existing agreement with Curium and the latest clinical data for uTREAT®, a qualified comparison can be made of what a future partnership agreement could potentially entail. Here is a direct comparison between the current Curium agreement and the potential that uTREAT® (therapy) possesses: 1. Comparison of agreement values: Curium agreement (uTRACE®) Product: uTRACE® (Diagnostics) Application: Prostate cancer (specific indication) Total value: Up to 70 million USD (~480 million DKK) Milestones: Development and commercial goals Royalties: "Double-digit" (typically 10-15%) Potential uTREAT® agreement Product: uTREAT® (Therapy) Application: Aggressive tumors (e.g. Glioblastoma) Total value: Significantly higher (estimated 300-600+ million USD) Milestones: Larger "upfront" and clinical milestones Royalties: Often higher for therapy (e.g. 15-20%+) 2. Why uTREAT® is more valuable than uTRACE®: There are three main reasons why an agreement based on the news from January 12, 2026, is expected to significantly exceed the Curium agreement: Therapy vs. Diagnostics: Historically, the market for cancer treatment (therapy) is many times larger than the market for diagnostics (scanning). While diagnostics helps find cancer, it is therapy that costs the most and creates the greatest value for pharmaceutical companies. As mentioned in market analyses, the market for glioblastoma treatment is estimated at over 5 billion EUR, while the diagnostics market is significantly smaller. "First-in-class" validation: The news from January 12 confirms for the first time in humans that uTREAT® actually reaches the brain tumor. This enormously reduces the risk ("de-risking") for a partner. The Curium agreement only covered uTRACE for one specific type of cancer (prostate), while uTREAT® can potentially be used for almost all solid tumors (>85%). Platform potential: A partnership agreement for uTREAT® will likely be structured as a "multi-indication" agreement. This means that the value can escalate quickly if the agent also shows effect in, for example, lung cancer or pancreatic cancer. 3. Estimation of size: If Curasight lands a partnership agreement for uTREAT® after their top-line data in Q2 2026, analysts will often look at similar agreements in the radiopharmaceuticals sector (such as Novartis' acquisitions or partnerships). Upfront payment: For uTRACE (Curium), the first milestones were relatively small (e.g. 500,000 USD). For uTREAT®, an upfront payment will likely be in the millions (USD) immediately to secure the rights. Total framework: A total agreement framework of 300-500 million USD is not unrealistic for a promising therapeutic candidate in the early clinical phases, when the platform is already diagnostically validated. Conclusion: A partnership agreement for uTREAT® will likely make the Curium agreement look like a "little brother". While the Curium agreement validated the technology, it is uTREAT® that will drive the really big economic value. Based on links and market practice, we can expect an agreement that is 5-10 times larger in total potential value than the current agreement with Curium.
Scubacore
12 t sitten
·
Scubacore
12 t sitten
·
It is important that Curasight maintains a good relationship with Curium as Curium is currently their supplier of Lu-177. There are of course other suppliers, but the collaboration with Curium is important in this phase of the projects.
alfredoo
16 t sitten
·
alfredoo
16 t sitten
·
Is anyone else wondering why the stock isn't reacting more to the latest positive news, which otherwise removed significant uncertainty in the case - and that it's even falling today? 🤔
TKHansen
15 t sitten
·
TKHansen
15 t sitten
·
So, 60 new owners came in yesterday, that's pretty good. It should rise and it will do so again soon (I think). There's always one or 2 who need cash and therefore sell off. New house, new car, expensive divorce etc ... life.
frufroe
10 t sitten
·
frufroe
10 t sitten
·
🤣🤣🤣🤣
asromadk
1 päivä sitten
·
asromadk
1 päivä sitten
·
Good revenue. If they can follow up now with something new and perhaps something in the pipeline, then it will suddenly get wild.
AllanL
1 päivä sitten
·
AllanL
1 päivä sitten
·
Can it be true that there are 36,000 shares for sale at price 12.5 at close ??? Oh, I'd really like to own them.....and keep them, just for about half a year....😅
AllanL
1 päivä sitten
AllanL
1 päivä sitten
🤣
bmotrader
1 päivä sitten
·
bmotrader
1 päivä sitten
·
Biostock regarding CURAS: https://www.biostock.se/en/2026/01/curasight-presenterar-preliminara-fas-i-data-for-utreat/
mads83
1 päivä sitten
mads83
1 päivä sitten
https://news.futunn.com/hk/post/67275129/curasight-announces-encouraging-preliminary-data-from-phase-1-trial-evaluating?level=1&data_ticket=1768308455937077 All around the world :P

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Spotlight Stock Market DK

Määrä

Osto

2 515

Myynti

Määrä

5 065

Viimeisimmät kaupat

Aika	Määrä	Ostaja	Myyjä
17.59.37	450	NON	NON
17.59.37	1 675	NON	NON
17.59.37	340	NON	NON
17.59.37	50	AVA	NON
17.44.26	100	NON	NON

Ylin

12,85

VWAP

12,47

Alin

12

VaihtoMäärä

1,6 127 302

VWAP

12,47

Ylin

12,85

Alin

12

VaihtoMäärä

1,6 127 302

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä